EBIT: Income before interest and taxes.
NurExone Biologic Inc. (NRXBF) had EBIT of $-6.32M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-6.38M |
|
-- |
|
-- |
|
$6.32M |
|
$-6.32M |
|
$-0.06M |
|
$-6.38M |
|
$-6.38M |
|
$-6.38M |
|
$-6.38M |
|
$-6.38M |
|
$-6.38M |
|
|
EBIT |
$-6.32M |
$-6.14M |
|
80.02M |
|
80.02M |
|
$-0.08 |
|
$-0.08 |
|
| Balance Sheet Financials | |
$2.60M |
|
$0.76M |
|
$1.48M |
|
$4.08M |
|
$0.99M |
|
-- |
|
$0.34M |
|
$1.32M |
|
$2.76M |
|
$2.76M |
|
$2.76M |
|
90.68M |
|
| Cash Flow Statement Financials | |
$-4.51M |
|
$-0.06M |
|
$5.83M |
|
$0.70M |
|
$2.14M |
|
$1.44M |
|
$1.29M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.63 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-4.57M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-231.47% |
|
-231.47% |
|
-156.36% |
|
-231.47% |
|
$0.03 |
|
$-0.06 |
|
$-0.06 |
|